Business Trip

Greg Kubin & Matias Serebrinsky
  • 0,0 (0)
  • Santé mentale
  • Tous les mois

Business Trip explores the frontiers of brain and mental health through conversations with founders, investors, and researchers at the intersection of neuroscience and technology.

  1. Virtual Mitochondrial Models and the Case for Engineering Humans with Mariëlle van Kooten

    -2 j

    Virtual Mitochondrial Models and the Case for Engineering Humans with Mariëlle van Kooten

    Mariëlle van Kooten (CEO and co-founder of Powerhouse Biology) joins to make the case that mitochondria are the best place to start engineering the human body. Her team builds virtual mitochondria models to predict how a fix will behave before it ever touches a patient. Marielle is passionate about treating disease and human enhancement.  In this episode, we discuss: Why mitochondria might be the most tractable place to start engineering human biologyThe difference between building a virtual mitochondria model and the industry-wide race to build a virtual cellWhy a protein fix for one disease (say, Parkinson's-linked muscle weakness) could work across totally unrelated tissuesThe difference between Science vs. Engineering: why she left academiaThe case for human enhancement: longevity, resilience, and why the ethics conversation is stalledCredits: Created by Greg Kubin and Matias Serebrinsky Host: Matias and Greg Produced by Nico V. Rey Find us at businesstrip.fm and psymed.ventures Follow us on Instagram and Twitter! Theme music by Dorian Love Additional Music: Distant Daze by Zack Frank

    24 min
  2. Brain Organoids: from Space to AI with Alysson Muotri

    14 mai

    Brain Organoids: from Space to AI with Alysson Muotri

    Professor Alysson R. Muotri (geneticist and developmental biologist at UC San Diego) joins for a far out conversation about sending brain organoids to the International Space Station and what they're teaching us about aging, neurological disease, and a new kind of AI. One month in orbit ages an organoid the equivalent of 10 years on Earth, and Alysson's lab has already used that compressed timeline to unlock an FDA-approved clinical trial for a drug developed in space. In this episode, we discuss: Why space accelerates brain agingThe surprising role of "junk DNA" and endogenous retroviruses in neuroinflammation and neurodegenerationWhy HIV antiretroviral drugs may be the key to treating neurological conditions What the decommissioning of the ISS and the rise of commercial space stations mean for biomedical researchHow brain organoids learn, remember, and inspire a new generation of AI algorithms beyond transformersThe bioethics frontier: when do organoids become conscious and how would we even know? Credits: Created by Greg Kubin and Matias Serebrinsky Host: Matias and Greg Produced by Nico V. Rey Find us at businesstrip.fm and psymed.ventures Follow us on Instagram and Twitter! Theme music by Dorian Love Additional Music: Distant Daze by Zack Frank

    34 min
  3. How Gilgamesh Landed a $1.2B AbbVie Deal in Psychedelics

    25 mars

    How Gilgamesh Landed a $1.2B AbbVie Deal in Psychedelics

    Jonathan Sporn (CEO + Founder of Gilgamesh Pharma) joins for a deep dive into next-gen psychedelic medicines, why duration matters for real-world clinical use, and what it takes to build these therapies the way large pharma would—culminating in a partnership with AbbVie worth up to $1.2B. In this episode, we discuss:  • Why Gilgamesh is building psychedelic medicines the way large pharma would  • The thesis behind short-acting psychedelics and why long-duration trips are impractical for real-world psychiatry  • How Gilgamesh designs molecules backwards from clinical needs  • Effective approaches to the challenges of trial designs for psychedelics   • What AbbVie’s deal and Spravato’s trajectory mean for psychedelics  • How psychedelic medicines could reshape mental health Credits: Created by Greg Kubin and Matias Serebrinsky Host: Matias and Greg Produced by Nico V. Rey  Find us at businesstrip.fm and psymed.ventures Follow us on Instagram and Twitter! Theme music by Dorian Love Additional Music: Distant Daze by Zack Frank

    26 min
  4. Inside Philanthropy’s Role in Mental & Brain Health

    27 janv.

    Inside Philanthropy’s Role in Mental & Brain Health

    Greg speaks with three leaders in mental health philanthropy: Alyson Nieman from Mindful Philanthropy, Sabrina Gracias from Ortus Foundation, and Christena Huntsman Durham from Huntsman Mental Health Foundation, each offering a distinct perspective on how funding decisions get made and where the biggest gaps remain. In this episode we discuss: Trends in mental health philanthropy, and the 10-year challenge: how the field moves from roughly $2B to $35B in annual funding.Funding the clinic of the future: a $150M philanthropic gift behind the Huntsman Mental Health Institute’s crisis care centerYouth mental health: how the Ortus Foundation is addressing regional gaps in the US Intermountain WestCredits: Created by Greg Kubin and Matias Serebrinsky Host: Greg Kubin Produced by Caitlin Ner & Nico V. Rey  Find us at businesstrip.fm and psymed.ventures Follow us on Instagram and Twitter! Theme music by Dorian Love Additional Music: Distant Daze by Zack Frank

    42 min
  5. Rick Perry on paving the way for Ibogaine in America

    19/12/2025

    Rick Perry on paving the way for Ibogaine in America

    Greg interviews Rick Perry, the former Governor of Texas and former U.S. Secretary of Energy and leading advocate for ibogaine, live at the Real Summit. In this episode, we discuss: How a former Texas governor moved from strict opposition to drugs to becoming a leading advocate for ibogaine after firsthand experience and veteran outcomes.Ibogaine’s impact on PTSD, opioid addiction, and traumatic brain injury, including Stanford-linked brain imaging data showing functional and structural improvement.How veterans are the proving ground that enabled Texas to commit $50M in public funding for ibogaine clinical trials.Why ibogaine requires intensive medical supervision and why rigorous trials are essential for legitimacy and scale.A vision where ibogaine reshapes addiction treatment, veteran care, and eventually criminal justice and homelessness policy.Credits: Created by Greg Kubin and Matias Serebrinsky Host: Greg Kubin Produced by Caitlin Ner & Nico V. Rey  Find us at businesstrip.fm and psymed.ventures Follow us on Instagram and Twitter! Theme music by Dorian Love Additional Music: Distant Daze by Zack Frank

    40 min
  6. Brain Shuttles: A New Path Into the Brain with James Gorman of the Wyss Institute

    24/11/2025

    Brain Shuttles: A New Path Into the Brain with James Gorman of the Wyss Institute

    Matias interviews James (Jim) Gorman MD PhD from the Wyss Institute. Jim is Principal Investigator on the Wyss Institute Brain Targeting Program (BTP). Jim leads a team developing new approaches to transport drugs through the blood brain barrier (BBB) into the CNS. In this episode, we discuss: Why the BBB blocks most modern drugs from entering the brain, creating the biggest bottleneck in neuroHow brain shuttles hijack natural transport pathways like the transferrin receptor to move drugs across the BBBHow new modalities that reach the brain can potentially treat diseases like Alzheimer’s, Parkinson’s, ALS, and lysosomal disorders Why delivery route of shuttles enable IV or subcutaneous dosing instead of invasive intrathecal injectionsHow early data shows that shuttle-enabled antibodies clear amyloid faster, at lower doses, and with fewer side effectsHow the field is accelerating through a pre-competitive consortium model that lets multiple companies share shuttle platformsCredits: Created by Greg Kubin and Matias Serebrinsky Host: Matias Serebrinsky Produced by Caitlin Ner & Nico V. Rey  Find us at businesstrip.fm and psymed.ventures Follow us on Instagram and Twitter! Theme music by Dorian Love Additional Music: Distant Daze by Zack Frank

    49 min
  7. AI and the future of therapy with Luis Voloch of Jimini Health

    16/10/2025

    AI and the future of therapy with Luis Voloch of Jimini Health

    Greg and Matias interview Luis Voloch, CEO and Co-Founder of Jimini Health, an AI behavioral health company. He previously co-founded and served as CTO of Immunai, where he applied machine learning to immunology and drug discovery.  In this episode, we discuss:  How LLMs expand the scope of machine learning from rule-based tasks to open-ended reasoning and dialogueWhy healthcare adoption is tiered, beginning with clinician-facing AI scribes and moving toward patient-facing companies with human-in-the-loop to enhance quality of careWhy human oversight is essential and how AI can augment complex clinical work instead of replacing itThe competitive advantage from workflows, data, and trust via purpose built AI systemsThe path toward precision psychiatry, where continuous, language-based interactions can generate rich behavioral data to inform diagnostics, treatment, and drug discoveryCredits: Created by Greg Kubin and Matias Serebrinsky Host: Matias Serebrinsky Produced by Caitlin Ner & Nico V. Rey  Find us at businesstrip.fm and psymed.ventures Follow us on Instagram and Twitter! Theme music by Dorian Love Additional Music: Distant Daze by Zack Frank

    38 min
  8. Startups, philanthropy, billionaires, academia, neuromodulation, psychedelics, AI and new therapies in bipolar, autism, and Parkinson’s with Rob Malenka

    23/09/2025

    Startups, philanthropy, billionaires, academia, neuromodulation, psychedelics, AI and new therapies in bipolar, autism, and Parkinson’s with Rob Malenka

    Matias interviews Rob Malenka. In this episode, we discuss: Why progress in psychiatry is slow because the brain is the most complex organ and many disorders are highly heterogeneousThe bottlenecks including weak replicability in research, academic politics, perverse incentives, and pharma’s avoidance of neuropsychiatryHow breakthroughs require early detection, rigorous science, and bridging academia with biotech through venture philanthropyHow success depends on mission-driven, ethical people who align science, capital, and patient impact.The opportunities in neuromodulation, data-driven precision medicine, and combination therapies.Credits: Created by Greg Kubin and Matias Serebrinsky Host: Matias Serebrinsky Produced by Caitlin Ner & Nico V. Rey  Find us at businesstrip.fm and psymed.ventures Follow us on Instagram and Twitter! Theme music by Dorian Love Additional Music: Distant Daze by Zack Frank

    1 h 33 min
Tout afficher (68)

À propos

Business Trip explores the frontiers of brain and mental health through conversations with founders, investors, and researchers at the intersection of neuroscience and technology.

Informations

  • Création
    Greg Kubin & Matias Serebrinsky
  • Années d’activité
    2020 - 2026
  • Épisodes
    68
  • Classification
    Tous publics
  • Copyright
    © 2026 Business Trip
  • Site web de l’émission
    Business Trip

Vous aimeriez peut‑être aussi